Home / Health / Breakthrough Treatment Doubles Survival for TNBC
Breakthrough Treatment Doubles Survival for TNBC
23 Apr
Summary
- New drug Dato-DXd nearly doubled progression-free survival for TNBC patients.
- The treatment targets TROP2 protein on cancer cells, delivering medicine directly.
- Dato-DXd showed fewer side effects than standard chemotherapy for patients.
A significant advancement in treating triple-negative breast cancer (TNBC) has emerged from a global clinical trial. The study tested datopotamab deruxtecan (Dato-DXd), a novel therapy designed to combat this aggressive form of cancer.
For patients with advanced TNBC, Dato-DXd demonstrated a remarkable impact, extending progression-free survival to 10.8 months from 5.6 months experienced with standard chemotherapy. This drug, belonging to the class of antibody-drug conjugates (ADCs), precisely targets cancer cells by latching onto the TROP2 protein.
The trial, involving 644 patients, also showed that Dato-DXd shrank tumors in 63% of participants, a notable improvement over chemotherapy's 29%. Median overall survival reached 23.7 months, offering substantial hope. Furthermore, the treatment was generally better tolerated than traditional chemotherapy, with fewer patients discontinuing due to side effects.
This breakthrough therapy is now under fast-track review by the U.S. Food and Drug Administration and other global health agencies, marking a potential new era in TNBC treatment.
